Cancer stem cells in bladder cancer: a revisited and evolving concept

Purpose of review Recently, the prospective isolation and characterization of cancer stem cells (CSCs) from various human malignancies revealed that they are resistant to radiation and chemotherapies. Therefore, CSCs may be the ‘roots’ and ideal target for therapeutic intervention. Here, we will focus on reviewing the historical perspective, recent literatures on bladder cancer stem cells and their clinical implications. Recent findings CSCs have been prospectively isolated from bladder cancer tissues from patient specimens, established cancer cell lines and xenografts, based on the expression of a combination of cell surface receptors, cytokeratin markers, drug transporters and the efficient efflux of the Hoechst 33 342 dye (side population). Further, global gene expression profiling of CSCs revealed an activated gene signature of CSCs similar to that of aggressive bladder cancer, supporting the concept that a tumor cell subpopulation is contributing to bladder cancer progression. Finally, our studies on the preclinical targeting of bladder CSCs in vitro and in xenografts using a blocking antibody for CD47 reveal promising efficacy. Summary Functionally distinct CSCs exist in human bladder cancer and can be prospectively isolated. Continuing research will be important to identify their cell of origin, programs balancing self-renewal and differentiation and to identify additional therapeutic options to target bladder CSCs.

[1]  Zhenqiu Liu,et al.  Aldehyde Dehydrogenase 1 A1–Positive Cell Population Is Enriched in Tumor-Initiating Cells and Associated with Progression of Bladder Cancer , 2010, Cancer Epidemiology, Biomarkers & Prevention.

[2]  E. Kurzrock,et al.  Three clonal types of urothelium with different capacities for replication , 2009, Cell proliferation.

[3]  J. Visvader,et al.  Keeping abreast of the mammary epithelial hierarchy and breast tumorigenesis. , 2009, Genes & development.

[4]  Howard Y. Chang,et al.  Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells , 2009, Proceedings of the National Academy of Sciences.

[5]  Ash A. Alizadeh,et al.  CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem Cells , 2009, Cell.

[6]  G. Parmigiani,et al.  Differentiation of a Highly Tumorigenic Basal Cell Compartment in Urothelial Carcinoma , 2009, Stem cells.

[7]  Xiaowei Yin,et al.  Subpopulations of Stem-like Cells in Side Population Cells from the Human Bladder Transitional Cell Cancer Cell Line T24 , 2009, The Journal of international medical research.

[8]  Anthony Atala,et al.  Urine derived cells are a potential source for urological tissue reconstruction. , 2008, The Journal of urology.

[9]  John C. Thomas,et al.  Directed differentiation of bone marrow derived mesenchymal stem cells into bladder urothelium. , 2008, The Journal of urology.

[10]  J. She,et al.  Identification of side population cells from bladder cancer cells by DyeCycle Violet staining , 2008, Cancer biology & therapy.

[11]  R. Isseroff,et al.  Label-retaining cells of the bladder: candidate urothelial stem cells. , 2008, American journal of physiology. Renal physiology.

[12]  Susan G Hilsenbeck,et al.  Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. , 2008, Journal of the National Cancer Institute.

[13]  J. Chang,et al.  Bladder Cancer Initiating Cells (BCICs) Are Among EMA−CD44v6+ Subset: Novel Methods for Isolating Undetermined Cancer Stem (Initiating) Cells , 2008, Cancer investigation.

[14]  Mark W. Dewhirst,et al.  Glioma stem cells promote radioresistance by preferential activation of the DNA damage response , 2006, Nature.

[15]  Elaine Fuchs,et al.  Epidermal stem cells of the skin. , 2006, Annual review of cell and developmental biology.

[16]  Brown Mh,et al.  The SIRP family of receptors and immune regulation. , 2006 .

[17]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  I. Weissman,et al.  AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukemia with 8;21 chromosomal translocation. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[19]  J. Dick,et al.  Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell , 1997, Nature Medicine.

[20]  M. Elhilali,et al.  Cellular heterogeneity in normal and neoplastic human urothelium: a study using murine monoclonal antibodies. , 1987, British Journal of Cancer.

[21]  W. Mackillop,et al.  Cellular heterogeneity in normal human urothelium: Quantitative studies of lectin binding , 1987, The Histochemical Journal.

[22]  W. Mackillop,et al.  Cellular heterogeneity in normal human urothelium: an analysis of optical properties and lectin binding. , 1986, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[23]  W. Mackillop,et al.  Cellular heterogeneity in normal and neoplastic human urothelium. , 1985, Cancer research.

[24]  I. Tannock,et al.  Comparison of growth of human bladder cancer in tissue culture or as xenografts with clinical and pathological characteristics. , 1984, Cancer research.

[25]  J. Trent,et al.  Development of an agar-methyl cellulose clonogenic assay for cells in transitional cell carcinoma of the human bladder. , 1979, Cancer research.

[26]  A. Barclay,et al.  The SIRP family of receptors and immune regulation , 2006, Nature Reviews Immunology.

[27]  M. Tseng,et al.  In vitro chemosensitivity of J-82 human bladder cancer cells , 2004, Urological Research.

[28]  S. Nordling,et al.  Intratumoral heterogeneity of DNA indexes in transitional cell bladder cancer: relation to tumor histology. , 1991, European urology.